Aspen Pharmacare has secured a deal with Johnson & Johnson to make and sell a COVID-19 vaccine under its own brand.
On Tuesday, Aspen SA said the new deal would form the basis for negotiations of a definitive agreement on the manufacturing and sale of an Aspen-branded vaccine throughout Africa.
The new vaccine will be called Aspenovax.
It said this was subject to the signing of the definitive agreement lasting until 31 December 2026.
As part of the deal, J&J will grant Aspen a licence to its intellectual property.
It will also supply the substance for the jabs.
Through a previous agreement with Johnson & Johnson, Aspen has been filling and finishing over a hundred-million doses for distribution in Africa.
This is good news for Africa, which has seen a slower rollout compared to western countries.
More Stories
NICD Reports New COVID-19 Cases In SA
U.S. Supreme Court Overturns Roe v. Wade, Ends Constitutional Right To Abortion
Eskom Warns Of Potential Stage Escalation Amid Protests
Monkeypox Is No Cause For Concern – Phaahla
No Plans To Call Off Search For Khaya Magadla
Eskom Warns Of Higher Stages Of Blackouts
Parliament To Receive Report In Four Months – Ramaphosa
South Africans No Longer Required To Wear Face Masks
NICD Reports 1 028 New COVID-19 Cases In SA
Winde Calls For Remaining COVID Restrictions To Be Dropped
No Request From Namibia On Theft Probe – Justice Dept
NICD Reports 1 087 New COVID-19 Cases In SA